Zobrazeno 1 - 10
of 249
pro vyhledávání: '"Marie-Cécile Le Deley"'
Autor:
Abel Cordoba, Estelle Gesta, Alexandre Escande, Alexandra Noeuveglise, Romain Cayez, Adrien Halty, Mohamed Tahar Ladjimi, Fabrice Narducci, Delphine Hudry, Carlos Martinez Gomez, Sofia Cordoba, Marie-Cécile Le Deley, Maël Barthoulot, Eric F. Lartigau
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Background and purposeImage-guided adapted brachytherapy (IGABT) is superior to other radiotherapy techniques in the treatment of locally advanced cervical cancer (LACC). We aimed to investigate the benefit of interstitial needles (IN) for a combined
Externí odkaz:
https://doaj.org/article/69ec7fd10c344f7780591fc0942692c1
Autor:
Victorine Trentesaux, Sophie Maiezza, Emilie Bogart, Marie-Cécile Le Deley, Emmanuel Meyer, Ludovic Vanquin, David Pasquier, Laurent Mortier, Xavier Mirabel
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionStereotactic radiotherapy (SBRT) potentially has a role in the management of oligometastatic melanoma. However, literature with data specific to this management is very limited. The objectives of this study were to evaluate the time to lo
Externí odkaz:
https://doaj.org/article/6ed36b0b628d4bda87087675cf662ed7
Autor:
Coralie Courtinard, Sophie Gourgou, William Jacot, Matthieu Carton, Olivier Guérin, Laure Vacher, Aurélie Bertaut, Marie-Cécile Le Deley, David Pérol, Patricia Marino, Christelle Levy, Lionel Uwer, Geneviève Perrocheau, Renaud Schiappa, Florence Bachelot, Damien Parent, Mathias Breton, Thierry Petit, Thomas Filleron, Agnès Loeb, Simone Mathoulin-Pélissier, Mathieu Robain, Suzette Delaloge, Carine Bellera
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence
Externí odkaz:
https://doaj.org/article/95e587a2739d4813945eb54f7074bcab
Autor:
Arthur Felix, Pablo Berlanga, Maud Toulmonde, Judith Landman‐Parker, Sarah Dumont, Gilles Vassal, Marie‐Cécile Le Deley, Nathalie Gaspar
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1589-1604 (2021)
Abstract Background Optimal Phase‐II design to evaluate new therapies in refractory/relapsed Ewing sarcomas (ES) remains imperfectly defined. Objectives Recurrent/refractory ES phase‐I/II trials analysis to improve trials design. Methods Comprehe
Externí odkaz:
https://doaj.org/article/b6c7f503d5e0493b98b803fc267a35b3
Autor:
Vincent Gamblin, Chloé Prod’homme, Adrien Lecoeuvre, André -Michel Bimbai, Joël Luu, Pierre-Alexandre Hazard, Arlette Da Silva, Stéphanie Villet, Marie-Cécile Le Deley, Nicolas Penel
Publikováno v:
BMC Palliative Care, Vol 20, Iss 1, Pp 1-10 (2021)
Abstract Background Home hospitalization at the end of life can sometimes be perturbed by unplanned hospital admissions (UHAs, defined as any admission that is not part of a preplanned care procedure), which increase the likelihood of death in hospit
Externí odkaz:
https://doaj.org/article/0fbc95979cd648b597482ecaa54038aa
Autor:
Igor Latorzeff, Eric Bruguière, Emilie Bogart, Marie-Cécile Le Deley, Eric Lartigau, Delphine Marre, David Pasquier
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Background/purposeDose-escalated external beam radiotherapy (RT) is effective in the control of prostate cancer but is associated with a greater incidence of rectal adverse events. We assessed the dosimetric gain and safety profile associated with im
Externí odkaz:
https://doaj.org/article/b8814eb781cf4099a401694f1142fdc6
Autor:
Antonin Vary, Loïc Lebellec, Frédéric Di Fiore, Nicolas Penel, Claire Cheymol, Emilia Rad, Farid El Hajbi, Astrid Lièvre, Julien Edeline, André Michel Bimbai, Marie-Cécile Le Deley, Anthony Turpin
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Most patients with advanced pancreatic adenocarcinoma (PA) treated with FOLFIRINOX experience adverse events requiring dose reduction. We aimed to assess the association between relative dose intensity (RDI) and disease control in a Europ
Externí odkaz:
https://doaj.org/article/c503d95fdec94c7eb3de50d752b7ba3e
Publikováno v:
BMC Medical Research Methodology, Vol 19, Iss 1, Pp 1-17 (2019)
Abstract Background Performing well-powered randomised controlled trials (RCTs) of new treatments for rare diseases is often infeasible. However, with the increasing availability of historical data, incorporating existing information into trials with
Externí odkaz:
https://doaj.org/article/56c7c84340f8470582cb5e739d00ed1d
Autor:
Pierre-Yves Cren, Nicolas Bertrand, Marie-Cécile Le Deley, Michaël Génin, Laurent Mortier, Pascal Odou, Nicolas Penel, Emmanuel Chazard
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Background: The gut microbiota has a key role in the regulation of the immune system. Disruption of the gut microbiota’s composition by antibiotics might significantly affect the efficacy of immune checkpoint inhibitors. In a study of patients trea
Externí odkaz:
https://doaj.org/article/eec0a76e36ae41cab0455160d757224a
Autor:
Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Axel Le Cesne, Emmanuelle Bompas, Jean-Yves Blay, Antoine Italiano, Olivier Mir, Thomas Ryckewaert, Yves Toiron, Luc Camoin, Anthony Goncalves, Nicolas Penel, Marie-Cécile Le Deley
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel. Methods Circulating pro/anti-angiogenic factors were assessed on day 1 (D1) and day 8 (D8). T
Externí odkaz:
https://doaj.org/article/8bc9c15293a74110ae91f43eb5bfec0e